Clinical Trial: A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07173478) titled 'A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis' on Sept. 07.

Brief Summary: To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis (AD)

Intervention: DRUG: OPA-15406

1% foam, topical, twice daily, for 4 weeks

DRUG: Vehicle

vehicle, topical, twice daily, for 4 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Published by HT Digital Content Services with permission fro...